Global Cardiac Biomarkers Market Size To Worth USD 69.44 Billion By 2033 | CAGR of 14.20%
Category: HealthcareGlobal Cardiac Biomarkers Market Size To Worth USD 69.44 Billion by 2033
According to a research report published by Spherical Insights & Consulting, the Global Cardiac Biomarkers Market Size is to grow from USD 18.40 Billion in 2023 to USD 69.44 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 14.20% during projected period.
Get more details on this report -
Browse key industry insights spread across 200 pages with 110 Market data tables and figures & charts from the report on the "Global Cardiac Biomarkers Market Size, Share, and COVID-19 Impact Analysis, By Type (Creatine Kinase, Troponins, Myoglobin, Ischemia Modified Albumin, Other Types), By Application (Acute Coronary Syndrome, Myocardial Infarction), By Biomarker (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, Others), By End User (Hospitals, Specialty Clinics), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033)." Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/cardiac-biomarkers-market
Cardiac biomarkers are endogenous substances that enter the bloodstream when the heart muscle is damaged or stressed. It is a powerful technique for preventing heart disease by monitoring heart cardiac biomarkers. Cardiac biomarkers are used to determine the risk of several cardiovascular diseases (CVDs), including myocardial infarction, congestive heart failure, and acute coronary syndrome (ACS). CK-MB, troponin I & T, myoglobin, BNPs, IMA, and a few others are cardiac biomarkers that are frequently used as part of an integrated diagnostic approach for CVDs. Global cardiac biomarkers market for cardiac biomarkers has grown significantly over forecast period. Healthcare practitioners are now working on detecting these markers to identify and diagnose crucial conditions such as myocardial infarction, heart attack, and acute coronary syndrome. The global cardiac biomarkers market is expected to grow due to the increased prevalence of cardiovascular diseases and robust research in cardiovascular therapies. Emerging markets, like India, offer significant growth opportunities for suppliers of cardiac diagnostic solutions due to the rising burden of cardiovascular diseases caused by conditions like high blood pressure, diabetes, and obesity. However, the cardiac biomarker market faces challenges such as limited specificity, adverse effects, delayed results, and technical issues related to sample collection and storage. Hence, these factors may impede the market growth of the global cardiac biomarkers market during the forecast period.
The troponins segment is anticipated to hold the greatest share of the global cardiac biomarkers market during the projected timeframe.
On the basis of type, the global cardiac biomarkers market is divided into creatine kinase, troponins, myoglobin, ischemia modified albumin, and other types. Among these, the troponins segment is anticipated to hold the greatest share of the global cardiac biomarkers market during the projected timeframe. The growth can be attributed to the troponin test is used to diagnose many disease conditions, such as myocardial infarction and acute coronary syndrome boosting segmental growth.
The acute coronary syndrome segment is anticipated to hold the greatest share of the global cardiac biomarkers market during the projected timeframe.
On the basis of application, the global cardiac biomarkers market is divided into acute coronary syndrome and myocardial infarction. Among these, the acute coronary syndrome segment is anticipated to hold the greatest share of the global cardiac biomarkers market during the projected timeframe. The segmental growth can be attributed to the growing prevalence of acute coronary syndrome increases segmental growth.
The troponin segment is predicted to hold the greatest share of the global cardiac biomarkers market during the estimated period.
On the basis of biomarker, the global cardiac biomarkers market is divided into troponin, creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), myoglobin, and others. Among these, the troponin segment is predicted to hold the greatest share of the global cardiac biomarkers market during the estimated period. The segmental growth can be attributed to the troponin biomarkers have an important role in diagnosing cardiac diseases, measuring the severity of cardiac events, guiding therapy decisions, and predicting patient outcomes.
The hospital segment is predicted to hold the greatest share of the global cardiac biomarkers market during the estimated period.
On the basis of end user, the global cardiac biomarkers market is divided into hospitals and specialty clinics. Among these, the hospital segment is predicted to hold the greatest share of the global cardiac biomarkers market during the estimated period. The segmental growth can be attributed to the rapid growth of hospital infrastructure in developing countries, as well as the integration of clinical laboratories into large hospitals, which have all contributed to increased global use of cardiac biomarker tests.
North America is expected to hold the largest share of the global cardiac biomarkers market over the forecast period.
Get more details on this report -
North America is expected to hold the largest share of the global cardiac biomarkers market over the forecast period. The developed healthcare infrastructure and widespread adoption of cardiac biomarkers as a diagnostic and prognostic tool have contributed to the region's growth. The growing senior population necessitates biomarker testing to detect disorders such as acute myocardial infarction, driving up demand for testing supplies. increases the risk of cardiovascular disease and places additional strain on the healthcare system, resulting in increased demand for cardiac biomarker markets. The presence of the key players in North America's cardiac biomarkers industry. All of these reasons are driving the cardiac biomarker market in North America.
Asia-Pacific is predicted to grow at the fastest pace in the global cardiac biomarkers market during the projected timeframe. The region's growth can be attributed to the advanced cardiac diagnostics are becoming more affordable, as nations modernize and increase disposable money. The rising prevalence of cardiovascular diseases (CVDs) in this region has increased the need for better diagnostics, government support for disease-specific research, and expenditures on healthcare. India has a higher incidence of coronary artery disease than other growing countries. As a result, these factors are driving the worldwide cardiac biomarker market.
Major vendors in the global cardiac biomarkers market include Roche Diagnostics Corporation, Thermo Fisher Scientific, Randox laboratories, Beckman Coulter, Siemens Healthcare, Ortho Clinical Diagnostics, Trinity Biotech, Meso Scale Diagnostics, Abbott Laboratories, BioMerieux, Becton, Dickinson and Co., Luminex Corporation, Bio-Rad Laboratories, Alere Inc., Others.
Recent Developments
- In September 2022, SRL diagnostics launched “heart assure’, a specialized test that predicts the risk of a cardiac event in a person. High sensitivity troponin I (hsTnI) is a simple blood test that can accurately predict a cardiac event or injury by providing a heart health risk score.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global cardiac biomarkers market based on the below-mentioned segments:
Global Cardiac Biomarkers Market, By Type
- Creatine Kinase
- Troponins
- Myoglobin
- Ischemia Modified Albumin
- Other Types
Global Cardiac Biomarkers Market, By Application
- Acute Coronary Syndrome
- Myocardial Infarction
Global Cardiac Biomarkers Market, By Biomarker
- Troponin
- Creatine kinase-MB (CK-MB)
- B-type Natriuretic Peptide (BNP)
- Myoglobin
- Others
Global Cardiac Biomarkers Market, By End User
- Hospitals
- Specialty Clinics
Global Cardiac Biomarkers Market, Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Uk
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?